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Summary Familial predisposition to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the
skin are apparent in the autosomal dominant syndromes naevoid basal cell carcinoma syndrome (NBCCS) and
multiple self-healing squamous epitheliomata (MSSE) respectively. The gene responsible for NBCCS has been
proposed to be a tumour-suppressor gene and is mapped to the same 2 Mb interval on 9q22.3 as the MSSE
gene ESSI. In an attempt to further map the NBCCS gene, we have examined loss of heterozygosity (LOH) in
16 sporadic BCCs and two familial BCCs using microsatellite markers located within the candidate gene
region. The overall frequency of LOH observed was 67% in the BCCs and partial or interstitial deletions were
found in eight tumours, with the highest LOH frequency at markers D9S280, D9S287 and D9S180. To
determine if the same genomic region also shows frequent LOH in tumours with a squamous phenotype, we
have examined 11 SCCs, four actinic keratoses and 13 cases of Bowen's disease for LOH at 9q22.3. An overall
LOH frequency of 50% was observed at D9S180, and occurred in all types of squamous tumours. In contrast,
a much lower LOH frequency of only 6% was found at the D9S287 locus. Our observation of different
patterns of LOH at 9q22.3 in sporadic BCCs and SCCs implies that more than one tumour-suppressor gene
might be located in this genomic region.
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Skin cancer is the most common cancer in the Western world
(Ko et al., 1994). A major part of these are non-melanoma
skin cancers with basal cell carcinomas (BCCs) accounting
for more than 75% and squamous cell carcinomas (SCCs) for
20% (Miller, 1991; Kwa et al., 1992). Both BCCs and SCCs
are derived from the same cell type, the keratinocyte, and
show clear biological and clinical differences. BCCs grow
slowly and are mainly locally aggressive, but rarely
metastasise, whereas SCCs grow faster and do metastasise
(Weedon, 1992). Basal cell carcinoma occurs predominantly
as sporadic cases but also as familial cases in an autosomal
dominant disease called the naevoid basal cell carcinoma
syndrome (NBCCS) (McKusick number 109400), having an
estimated minimum incidence of 1 in 55 600 (Evans et al.,
1993). NBCCS predisposes to multiple BCCs, and some other
types of tumours such as ovarian fibromas, medulloblastomas
and cardiac fibromas. The disease is also associated with
widespread developmental defects (Gorlin, 1987). Squamous
cell carcinoma on the other hand occurs almost exclusively as
sporadic cases, although in a rare autosomal dominant
disease called multiple self-healing squamous epitheliomata
(MSSE) (McKusick number 132800) tumours morphologi-
cally similar to well-differentiated SCCs are seen (Goudie et
al., 1993). Through linkage analysis of kindreds with NBCCS
the gene for this syndrome has been mapped to the 9q22-31
region (Farndon et al., 1992; Gailani et al., 1992; Reis et al.,
1992; Chenevix-Trench et al., 1993). Further mapping has
limited the candidate genomic region to a 2 Mb interval on
9q22.3 between microsatellite markers D9S196 and D9S180
(Goldstein et al., 1994; Wicking et al., 1994), whereas the
interval between markers D9S12/D9S151 and D9S287 was
implicated in another study (Farndon et al., 1994). With
regard to the disorder MSSE the corresponding gene, ESSI,
has also been mapped to chromosome 9q22-31 (Goudie et
al., 1993), with a likely location in the interval between
D9S196 and D9S180 (Povey et al., 1994).
The NBCCS gene has been proposed to be a tumour-
suppressor gene based on the finding of frequent loss of
heterozygosity (LOH) in the NBCCS genomic region, 9q22-
31, in both sporadic and familiar BCCs, and in other tumour
types seen in the syndrome such as medulloblastomas
(Gailani et al., 1992; Quinn et al., 1994a; Schofield et al.,
1995). Further evidence that supports the tumour-suppressor
gene theory is that the allele deleted in BCCs from NBCCS
patients was found to be the non-disease-transmitting allele
(Bonifas et al., 1994). As the NBCCS and the ESSI genes
map to the same genomic region it has been speculated that
either two different genes reside in this area or that different
mutations in the same gene may explain the different clinical
features of the two disorders. Although there have not been
any studies of LOH on chromosome 9q in tumours from
MSSE patients, loss of chromosome 9q alleles have been
reported in sporadic skin SCCs (Quinn et al., 1994b;
Zaphiropoulos et al., 1994).
In order to confirm the frequent loss of the 9q22.3 area by
LOH in BCCs and to further map the NBCCS gene region,
we have examined sporadic and familiar BCCs for the
occurrence of LOH using microsatellite markers located
within the candidate area. To test the hypothesis that a gene
in the same chromosomal area may be involved in the
development of the squamous type of skin tumours we have
also investigated the frequency of 9q22.3 loss in SCCs, and in
the premalignant skin lesions actinic keratoses and Bowen's
disease.
Materials and methods
Tissue samples and DNA isolation
Sixteen sporadic BCCs, two BCCs from a patient with
NBCCS, 11 SCCs, four actinic keratoses, and 13 cases of
Bowen's disease were studied. Actinic keratoses are, often
multiple, sun-induced skin lesions that, if left untreated, can
progress to SCCs. Bowen's disease is SCC in situ of the skin,
with 8% of untreated cases developing into invasive SCCs
(Weedon, 1992). The tumour material and matched normal
tissue were selected from archival specimens from the
Department of Pathology at Huddinge University Hospital.
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February 1996Genomic DNA was extracted from paraffin sections of
trimmed tumours judged to contain >50% tumour cells
and from matched normal tissue. A 150 um section of each
sample was used for DNA extraction, performed according
to method described elsewhere (Ma et al., 1994) using
Nucleon (Scotlab Ltd, Strathclyde, UK) with the following
modifications. Before DNA extraction paraffin was removed
by adding 100 jAl of NIB buffer (0.45% NP40, 0.45%
TWEEN 20, 50 mM potassium chloride, 10 mM Tris
pH 8.3, 1.5 mm magnesium chloride and 100 ,ug ml-I
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gelatine) to the sample and boiling for 20 min followed by
a 10 min centrifugation at 13 000 r.p.m. The supernatant was
removed and used for further processing.
Detection of loss ofheterozygosity
Four microsatellite markers from the putative NBCCS/ESSJ
area on chromosome 9q22.3 (D9S196, D9S280, D9S287,
D9S180) were used to genotype the tumours and correspond-
ing normal tissue using the polymerase chain reaction (PCR).
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Figure 1 Analysis of loss ofheterozygosity (LOH) at the D9S180 microsatellite locus in a basal cell carcinoma (BCC), tumour no. 4. Allele
sizes are 220 and 228 bp. The x-axis denotes size in base pairs and the y-axis peak height values. The table shows the peak size (in base
pairs), peak height and peak area (arbitrary units). In the tumour, lane 3, there is a loss of the 228 allele resulting in an allele ratio of 0.34
compared with the normal DNA, lane 4.
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The amplifications were performed in a total volume of 10 Ml
containing 5 pmol of primer (one primer fluorescently
labelled, all primers were synthesised on an Expedite nucleic
acid synthesis system (Millipore AB, Sundbyberg, Sweden),
0.75 units Taq DNA Polymerase (Promega, Scandinavian
Diagnostic Services, Falkenberg, Sweden), 10 mM Tris
pH 9.0, 50 mm potassium chloride, 0.1% Triton X-100,
2.0 mm magnesium chloride, 200 gIM dNTPs and 70-
150 ng of sample DNA. This was overlaid with mineral oil.
Each sample was amplified with annealing temperatures of
61°C (D9S180), 63°C (D9S287), 66°C (D9S280) and 59°C
(D9S196) for 1 min in a DNA Thermal Cycler 480 (Perkin
Elmer AB, Sundbyberg, Sweden). Denaturation and exten-
sion temperatures of 94°C and 72°C for 1 min each were used
for all reactions, with a final 10 min extension at 72'C. The
cycle number was optimised for each DNA sample to ensure
that the PCR products were detectable but not overamplified.
The sequences of the primers were as listed (Gyapay et al.,
1994), except for D9S287, which were as follows 5'-ATC
ACA GGA TGC TCC TCA CGC and 5'-CTA ACC ACT
ACA TTG TTC AAG GG and for D9S280 primer sequences
were 5'-TCT TTT TCG CTT CCC ACC CA and 5'-CAC
GCC ACT GAT CTA GGC T. The PCR products were
analysed on 6% polyacrylamide denaturing gels in 1 x TBE
buffer in an ABI 373A automated DNA sequencer (Applied
Biosystems, Foster City, CA, USA), and subsequently
analysed by Genescan 672 (Applied Biosystems, Foster
City, CA, USA) for size, peak height and peak area. The
method described previously (Cawkwell et al., 1993), was
used to determine LOH, relating the allelic imbalance of a
tumour (T1:T2) to the imbalance in normal DNA (N1:N2)
using the expressions T1:T2/N1:N2, or 1/ (T1:T2/ N1:N2) if
allele ratio is above 1.00. Allele ratio values less or equal to
0.60 were scored as LOH.
Results
Eighteen BCCs, 11 SCCs, four actinic keratoses and 13 cases
of Bowen's disease were examined for LOH on chromosome
9q22.3, a region to which the NBCCS and ESSI gene(s) have
been located. In both syndromes a predisposition to non-
melanoma skin cancer is evident. Analysis of LOH was
performed using an ABI automated DNA sequencer and
evaluated with the Genescan software. An example
demonstrating LOH at D9S180 in a BCC (tumour 4) is
shown in Figure 1. All 18 BCCs were informative at one or
more loci from 9q22.3. Loss of heterozygosity of the different
microsatellite markers was seen in 30-57% of the
informative samples (Figure 2). Loss of heterozygosity for
at least one locus in the 9q22.3 area was observed in 67%
(12/18) of the BCCs. Partial or interstitial deletions in the
putative NBCCS/ESS1 gene region between D9S196 and
D9S180 were clearly detected in eight tumours, and possible
partial or complete deletions were found in an additional four
tumours (Figure 2). One tumour showed LOH for all
markers in the region. The most common deleted region
was between D9S180 and D9S280, with a lower frequency at
D9S196. One of the tumours, no. 8, showed loss at D9S280
only, with retained normal alleles at D9S287 and D9S196. In
tumours no. 1 and no. 16 LOH was seen only at the D9S180
locus. Tumour no. 15 showed loss at D9S280, was non-
informative for D9S196 and retained normal alleles at
D9S287. In tumour no. 17, obtained from an NBCCS
patient, the chromosome region lost is derived from the
non-disease-carrying chromosome as expected for a putative
tumour-suppressor gene (B. Unden, personal communica-
tion). The other tumour from this patient did not show LOH
for the two informative markers (D9S180 and D9S287) in the
region (data not shown). All BCCs analysed were of the solid
or micronodular type, classified according to WeedoN (1992).
Of the tumours with LOH 8/12 were from sun-exposed sites
(head/neck), which was consistent with the proportion of all
BCCs (14/18) located on sun-exposed sites. No tumour
showed additional bands with any of the four microsatellite
markers in the NBCCS/ESSJ region.
Loss of heterozygosity of the microsatellite marker
D9S180 was seen in 7/14 (50%) of the informative samples
in all subtypes of skin cancer with a squamous phenotype,
compared with the microsatellite marker D9S287 where loss
was only seen in one tumour (actinic keratoses), correspond-
ing to only 6% (1/18) of the informative samples (Table I).
Two tumours, no. 13 Bowen's disease and no. 4 SCC had
probably lost the whole NBCCS/ESSJ region (Figure 3). All
tumours with LOH at 9q22.3 involved loss at D9S180. Eight
of 11 SCCs, 4 of 13 cases of Bowen's disease and four of four
actinic keratoses were located on sun-exposed sites, mainly
the head/neck region. Remaining tumours were commonly
found on the chest or back regions. Tumours showing LOH
were predominantly found in the head/neck region (five out
of seven). However, two tumours of the Bowen's disease type
located on the breast and chest respectively also showed LOH
at D9S180. Extra bands indicating replication errors (RER)s
were not seen in any subtype of the squamous skin tumours
with the microsatellite markers used.
Discussion
In the present study the high overall frequency, 67%, of LOH
on 9q22.3 in sporadic BCCs confirm earlier reports (Gailani
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Figure 2 Pattern of loss on chromosome 9q22.3 in basal cell
carcinomas (BCCs) showing loss of heterozygosity (LOH). The
proportion of informative tumours showing LOH at each locus is
given. Tumour no. 17 is from a patient with the naevoid basal cell
carcinoma syndrome (NBCCS). *, Loss ofheterozygosity; fO, no
loss of heterozygosity; M non-informative.
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Figure 3 Pattern of loss on chromosome 9q22.3 in squamous cell
carcinomas (SCCs), Bowen's disease (BD) and actinic keratoses
(AK) showing loss of heterozygosity (LOH). *, Loss of
heterozygosity; El, no loss of heterozygosity; E non-
informative.
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Table I Loss of heterozygosity at chromosome 9q22.3 in squamous cell carcinomas. Bowen's disease and actinic keratoses
Squamous cell carcinoma Bowen's disease Actinic keratoses All tumours
(n= 1]) (n= 13) (n=4) (n= 78)
Cases with Informative Cases with Informative Cases with Informative Cases with Informative
Markers loss cases loss cases loss cases loss cases
D9S180 2 4 4 8 1 2 7 14
D9S287 0 8 0 8 1 2 1 18
et al.. 1992; Quinn et al.. 1994c: Shanley et al.. 1995). and
strongly implicates inactivation of a tumour-suppressor gene
in this genomic region as a central molecular genetic change
in this type of skin cancer. This is further supported by the
finding that LOH at 9q22-31 occurs in BCCs derived from a
Japanese population. where only a few ras mutations (Liew et
al., 1991) and no p53 mutations are found (Konishi et al..
1994). Additionally. LOH at 9q22-31 is a more frequent
event than alterations at the p53 locus in Western
populations (Ziegler et al.. 1993; van der Riet et al.. 1994).
In fact. in one study inactivation of only one p53 allele was
observed in BCCs showing LOH on 9q22-31. suggesting
that p53 and the putative tumour-suppressor gene on 9q22.3
may act in a cooperative manner (van der Riet et al.. 1994).
Alternatively, it is possible that the single p53 mutations
represent dominant gain of function type of mutations.
Assuming that the gene inactivated in sporadic BCCs is
identical to the NBCCS gene. consistent with the observed
loss of the non-disease-transmitting allele in the familial
BCCs. our analysis of eight tumours with clear partial or
interstitial deletions and four tumours with possible partial or
complete deletions provide information as regards the
potential location of this gene. The most commonly deleted
markers were D9S280, D9S287 and D9S180 with a lower
frequency at D9S196. suggesting that the gene is likely to be
found in an interval encompassing the former markers but
distal to D9S196. Interestingly. deletions in two tumours
would favour a location distal to D9S287, whereas two other
tumours indicate a location proximal to this marker with one
tumour showing loss of the D9S280 marker only. These
findings are not consistent with the recently suggested
smallest region of overlap between markers D9S287 and
D9S180 (Shanley et al.. 1995). However, in their study the
putative location was based on information derived from
only two sporadic BCCs. One possible way to reconcile the
pattern of LOH observed in our study and published critical
recombinants placing the gene between D9S196 and D9S287
(Farndon et al.. 1994: Wicking et al.. 1994) is if the D9S287
marker is intragenic to the NBCCS gene. The only genes
presently known to be located in the interval between
D9S196 and D9S180 is Fancom' anaemia group C (FACC)
and xeroderma pigmentosum complementation group A
(XPAC). which both have been excluded as the NBCCS
gene based on mutational analysis (Bare et al., 1995).
In SCCs of the skin and premalignant lesions such as
actinic keratoses and Bowen's disease a strikingly different
pattern of LOH was observed with a high frequency of LOH
(50%) observed at D9S180 but essentially no loss (6%) at
D9S287. Whether a new putative tumour-suppressor gene of
importance for development of SCCs resides at or distal to
D9S180. with the marker D9S287 as the proximal border of
the deleted region, remains to be investigated by further
deletion mapping using markers distal to D9S180. One
previous study reported only a low frequency of LOH at
9q22.3 in SCCs in spite of more overall widespread genetic
changes compared with BCCs (Quinn et al.. 1994c). However.
in a subsequent study from the same group a LOH frequency
of 44% in this genomic region in actinic keratoses was
observed (Rehman et al.. 1994). It is also highly interesting to
note that frequent LOH in the 9q22-34 area has been
reported in squamous cell carcinomas from other tissues such
as oesophagus, head and neck and bladder (Ah-See et al..
1994: Mon' et al., 1994; Habuchi et al.. 1995; Miura et al..
1995). Furthermore. consistent with our observation of LOH
at D9SI80 already in premalignant lesions, these studies also
support the notion that loss of genetic material on 9q is an
early event in development of squamous cell cancer. whereas
loss on 9p in the region harbouring the CDKN2 gene (also
called MUTSJ) appears later.
We did not detect RERs in the tumours analysed. which is
consistent with earlier reports finding microsatellite length
alterations at more than one loci to be rare in non-melanoma
skin cancer (Zaphiropoulos et al.. 1994: Quinn et al.. 1995).
In one of the studies (Zaphiropoulos et al.. 1994). however.
frequent RERs were observed in SCCs at one marker.
D9S109, located distally to D9SI80 and therefore potentially
included in the region showing frequent LOH in SCCs.
Taken together. the data suggest that RERs at multiple loci is
an uncommon event in skin cancer.
UV radiation is considered to be the most important
aetiological factor for development of both BCCs and SCCs
(Ko et al., 1994: Gallagher et al.. 1995a.b) and a high
frequency of UV-related mutations in the p53 gene. mainly C
to T and CC to TT. have been found in both types of
tumours (Brash et al.. 1991: Ziegler et al.. 1993; van der Riet
et al.. 1994). It is therefore tempting to believe that UV
radiation may also be a key factor behind the genetic
alterations on 9q. There are. however. several reasons to
think that other. so far unknown. causative factors may play
a role. Firstly. LOH on 9q was observed in both BCCs and
Bowen's disease derived from sites not regularly sun exposed
and secondly. LOH was found in BCCs from a Japanese
population lacking UV-related p53 mutations (Konishi et al..
1994). Admittedly. it still remains possible that appearance of
LOH is favoured as a primary event during a severe sunburn
and that subsequent p53 mutations are more closely related
to accumulated sun exposure.
In summary., analysis of LOH at 9q22.3 in sporadic BCCs
suggest that the putative tumour-suppressor gene, most likely
identical to the NBCCS gene. resides in a region encompass-
ing the markers D9S280, D9S287 and D9S180 and is
compatible with an intragenic location of the marker
D9S287. Moreover, the different pattern of LOH in SCCs
and premalignant lesions implies that loss of a putative
tumour-suppressor gene important in development of the
squamous type of skin cancers might be located in or distal
to this area.
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